EPILEPSY UNIT HOSPITAL DEL MAR

Publications with impact factor<< Back

  1. A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures. Rocamora R. Ther Adv Neurol Disord. 2015 Jul;8(4):178-86.
  2. Perfusion SPECT, SISCOM and PET 18F-FDG in the assessment of drug- refractory epilepsy patients candidates for epilepsy surgery. Suárez-Piñera M, Mestre-Fusco A, Ley M, González S, Medrano S, Principe A, Mojal S, Conesa G, Rocamora R. Rev Esp Med Nucl Imagen Mol. 2015 Nov-Dec;34(6):350-357.
  3. Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate-Expert opinion. Peltola J, Holtkamp M, Rocamora R, Ryvlin P, Sieradzan K, Villanueva V. Epilepsy Behav. 2015 Sep;50:46-9.
  4. Intraoperative Neurophysiological Evidence of Hydrogen Peroxide-Induced Stroke in Insular Tumor Surgery. León Jorba A, López Cuiña M, Principe A, Villalba Martínez G. Turk Neurosurg. 2015;25(4):674-7.
  5. A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. De Sola S, de la Torre R, Sánchez-Benavides G, Benejam B, Cuenca-Royo A, Del Hoyo L, Rodríguez J, Catuara-Solarz S, Sanchez-Gutierrez J, Dueñas-Espin I, Hernandez G, Peña-Casanova J, Langohr K, Videla S, Blehaut H, Farre M, Dierssen M; TESDAD Study Group. Front Psychol. 2015 Jun 4;6:708.
  6. Safety study of long-term video-electroencephalogram monitoring. Ley M, Vivanco R, Massot A, Jiménez J, Roquer J, Rocamora R. Neurologia. 2014 Jan-Feb;29(1):21-6
  7. Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results. Massot A, Vivanco R, Principe A, Roquer J, Rocamora R. Neurologia. 2014 Mar;29(2):94-101.
  8. The pivotal role of the supplementary motor area in startle epilepsy as demonstrated by SEEG epileptogenicity maps.  Job AS, De Palma L, Principe A, Hoffmann D, Minotti L, Chabardès S, David O, Kahane P. (2014). Epilepsia. 2014 Aug;55(8)
  9. Pilomotor seizures: an autonomic semiology of limbic encephalitis? Rocamora R, Becerra JL, Fossas P, Gomez M, Vivanco-Hidalgo RM, Mauri JA, Molins A. Seizure. 2014 Sep;23(8):670-3
  10. Assessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver función tests. Ley M, Principe A, Jiménez-Conde J, Rocamora R. Epilepsy Res. 2015 Sep;115:147-52.
  11. Sleep modulation of epileptic activity in mesial and neocortical temporal lobe epilepsy: a study with depth and subdural electrodes. Rocamora R, Andrzejak RG, Jiménez-Conde J, Elger CE. Epilepsy Behav. 2013 Aug;28(2):185-90.
  12. Comparison of polysomnographic variables and their relationship to cognitive impairment in patients with Alzheimer's disease and frontotemporal dementia. Kundermann B, Thum A, Rocamora R, Haag A, Krieg JC, Hemmeter U. J Psychiatr Res. 2011 Dec;45(12):1585-92
  13. Familial recurrent hypersomnia: two siblings with Kleine-Levin syndrome and menstrual-related hypersomnia. Rocamora R, Gil-Nagel A, Franch O, Vela-Bueno A. J Child Neurol. 2010 Nov;25(11):1408-10.
  14. EEG extreme delta brush: An ictal pattern in patients with anti-NMDA receptor encephalitis. Veciana M, Becerra JL, Fossas P, Muriana D, Sansa G, Santamarina E, Gaig C, Carreño M, Molins A, Escofet C, Ley M, Vivanco R, Pedro J, Miró J, Falip M. Epilepsy Behav. 2015 Aug;49:280-5. Jun 10.
  15. Development and validation of a liquid chromatography-tandem mass spectrometry assay for hair analysis of atomoxetine and its metabolites: Application in clinical practice. Papaseit E, Marchei E, Mortali C, Aznar G, Garcia-Algar O, Farrè M, Pacifici R, Pichini S. Forensic Sci Int. 2012 May 10;218(1-3):62-7.
  16. Comprehensive molecular testing in patients with high functioning autism spectrum disorder. Alvarez-Mora MI, Calvo Escalona R, Puig Navarro O, Madrigal I, Quintela I, Amigo J, Martinez-Elurbe D, Linder-Lucht M, Aznar Lain G, Carracedo A, Mila M, Rodriguez-Revenga L. Mutat Res. 2016 Feb-Mar;784-785:46-52.
  17. Children often present with infantile spasms after herpetic encephalitis. Aznar Laín G, Dellatolas G, Eisermann M, Boddaert N, Chiron C, Bulteau C, Monteiro JP, An I, Pédespan JM, Cancès C, Peudenier S, Barthez MA, Milh M, Dorfmuller G, Héron B, Nabbout R, Grevent D, Dulac O. Epilepsia. 2013 Sep;54(9):1571-6.
  18.  [Thallium poisoning in an adolescent girl]. López Segura N, Aznar Laín G, Nolla Salas J, Mur Sierra A. Med Clin (Barc). 2013 Dec 21;141(12):557-8.
  19. [1p36 microdeletion syndrome]. Ortigosa Gómez S, Seidel Padilla V, Cuscó I, Aznar Lain G. An Pediatr (Barc). 2011 Mar;74(3):197-9.
  20. [Epstein-Barr meningo-encephalitis in a healthy boy]. Aznar Laín G, Martinez Roig A, Castejón Ponce E, López Segura N, Muñoz Almagro C, Bonet Alcaina M. An Pediatr (Barc). 2010 Jun;72(6):445-6.
  21. Seizures and epilepsy in hypoglycaemia caused by inborn errors of metabolism. Gataullina S, Delonlay P, Lemaire E, Boddaert N, Bulteau C, Soufflet C, Laín GA, Nabbout R, Chiron C, Dulac O. Dev Med Child Neurol. 2015 Feb;57(2):194-9.
  22. Comprehensive molecular testing in patients with high O profesionales relacionadosfunctioning autism spectrum disorder. Alvarez-Mora MI, Calvo Escalona R, Puig Navarro O, Madrigal I, Quintela I, Amigo J, Martinez-Elurbe D, Linder-Lucht M, Aznar Lain G, Carracedo A, Mila M, Rodriguez-Revenga L.
  23. Mutat Res. 2016 Feb-Mar;784-785:46-52
  24. Effectiveness of antiepileptic therapy in patients with PCDH19 mutations. Lotte J, Bast T, Borusiak P, Coppola A, Cross JH, Dimova P, Fogarasi A, Graneß I, Guerrini R, Hjalgrim H, Keimer R, Korff CM, Kurlemann G, Leiz S, Linder-Lucht M, Loddenkemper T, Makowski C, Mühe C, Nicolai J, Nikanorova M, Pellacani S, Philip S, Ruf S, Sánchez Fernández I, Schlachter K, Striano P, Sukhudyan B, Valcheva D, Vermeulen RJ, Weisbrod T, Wilken B, Wolf P, Kluger G. Seizure. 2016 Feb;35:106-10.
  25. Microdeletion 5q14.3 and anomalies of brain development. Hotz A, Hellenbroich Y, Sperner J, Linder-Lucht M, Tacke U, Walter C, Caliebe A, Nagel I, Saunders DE, Wolff G, Martin P, Morris-Rosendahl DJ. Am J Med Genet A. 2013 Sep;161A(9):2124-33.
  26. Hip lateralisation in children with bilateral spastic cerebral palsy treated with botulinum toxin type A: a 2-year follow-up. Jung NH, Heinen F, Westhoff B, Doederlein L, Reissig A, Berweck S, Linder-Lucht M, Schandelmaier S, Mall V; German Abo study group. Neuropediatrics. 2011 Feb;42(1):18-23.


Internal campaigns

  • Pla d'igualtat del PSMar
  • Hospitals sense fum
  • Hospitals sostenibles

Social networks

  • Twitter
  • Canal YouTube

© 2006 - 2019 Parc de Salut Mar · Legal notice | Cookie Policy | Accessibility